Hyderabad, India, February 10, 2025 – NATCO Pharma Limited (NSE: NATCOPHARM, BSE: 524816) has announced that it has received the final approval for its Abbreviated New Drug Application (ANDA) for Bosentan Tablets for Oral Suspension (TFOS), 32 mg, a generic version of Tracleer® by Actelion Pharmaceuticals US Inc. The company’s marketing partner, Lupin Pharmaceuticals, Inc., will handle the product launch in the U.S.Key Highlights of the Approval:First-to-File Status: NATCO Pharma has...